Health Mubadala pharma subsidiary makes four acquisitions from Yas By Neil Halligan October 14, 2024, 6:16 PM Olaf Doering/Alamy via Reuters Wellpharma, one of the four Mubadala pharma acquisitions, specalises in dialysis equipment and intravenous therapies Mubadala buys Yas pharma companies Under Kelix Bio subsidiary Targeting life sciences growth Mubadala Investment Company’s newly acquired subsidiary, Kelix Bio, has bought four pharma assets from Yas Holdings’ healthcare unit, GlobalOne Healthcare Holdings. Kelix Bio purchased Bioventure, Bioventure Healthcare, Gulf Inject and Wellpharma, the Abu Dhabi sovereign wealth fund Mubadala said on Monday. The value of the deal was not disclosed. Mubadala said the four acquisitions would support Kelix Bio’s regional growth and strengthen its life sciences presence in the UAE. Bioventure is a biopharmaceutical company with a global presence which specialises in biotech and generics commercialisation, bringing lower-cost, equivalent versions of branded pharmaceuticals to market after the original patents expire, as well as tech transfer and licensing. Bioventure Healthcare produces soft gelatine capsules for pharmaceutical and supplement products and is expanding into oral solids and injectables. Gulf Inject is a specialist in sterile fluid management therapy (the administration and monitoring of intravenous fluids), parenteral therapy and healthcare manufacturing products. Wellpharma’s focus is the production of intravenous therapies and dialysis equipment, along with other therapeutic products, in the UAE and the Mena region. Mubadala joins $680m acquisition of UCB’s Chinese business Affordable healthcare in the GCC: a prescription for profit Aster DM Gulf unit explores $250m Saudi expansion In March, Mubadala signed a definitive agreement to acquire Kelix Bio, a speciality pharmaceutical business in the UAE which focuses on delivering complex generics in emerging markets. The deal was concluded in September. “Kelix Bio and its assets are well positioned for accelerated growth and will enable us to deliver on our ambition of creating a regional life sciences champion,” said Dr Bakheet Al Katheeri, the CEO of UAE Investments Platform at Mubadala. Mubadala said the acquisition of the four businesses aligns with government initiatives such as Operation 300bn and Make it in the Emirates, which aim to strengthen the country’s manufacturing sector and promote domestic manufacturing.